Header Logo

Connection

Gregory Clarke to Venlafaxine Hydrochloride

This is a "connection" page, showing publications Gregory Clarke has written about Venlafaxine Hydrochloride.
Connection Strength

0.417
  1. The bidirectional relationship between body mass index and treatment outcome in adolescents with treatment-resistant depression. J Child Adolesc Psychopharmacol. 2013 Sep; 23(7):458-67.
    View in: PubMed
    Score: 0.029
  2. Impact of treatments for depression on comorbid anxiety, attentional, and behavioral symptoms in adolescents with selective serotonin reuptake inhibitor-resistant depression. J Am Acad Child Adolesc Psychiatry. 2013 May; 52(5):482-92.
    View in: PubMed
    Score: 0.028
  3. The bi-directional relationship between parent-child conflict and treatment outcome in treatment-resistant adolescent depression. J Am Acad Child Adolesc Psychiatry. 2013 Apr; 52(4):370-7.
    View in: PubMed
    Score: 0.028
  4. Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatment-resistant depression. J Am Acad Child Adolesc Psychiatry. 2012 Apr; 51(4):404-11.
    View in: PubMed
    Score: 0.026
  5. Out of the black box: treatment of resistant depression in adolescents and the antidepressant controversy. J Child Adolesc Psychopharmacol. 2012 Feb; 22(1):5-10.
    View in: PubMed
    Score: 0.026
  6. Adjunctive sleep medications and depression outcome in the treatment of serotonin-selective reuptake inhibitor resistant depression in adolescents study. J Child Adolesc Psychopharmacol. 2012 Feb; 22(1):29-36.
    View in: PubMed
    Score: 0.026
  7. Treatment-resistant depressed youth show a higher response rate if treatment ends during summer school break. J Am Acad Child Adolesc Psychiatry. 2011 Nov; 50(11):1140-8.
    View in: PubMed
    Score: 0.025
  8. Suicide attempts and nonsuicidal self-injury in the treatment of resistant depression in adolescents: findings from the TORDIA study. J Am Acad Child Adolesc Psychiatry. 2011 Aug; 50(8):772-81.
    View in: PubMed
    Score: 0.025
  9. Pharmacokinetically and clinician-determined adherence to an antidepressant regimen and clinical outcome in the TORDIA trial. J Am Acad Child Adolesc Psychiatry. 2011 May; 50(5):490-8.
    View in: PubMed
    Score: 0.024
  10. Long-term outcome of adolescent depression initially resistant to selective serotonin reuptake inhibitor treatment: a follow-up study of the TORDIA sample. J Clin Psychiatry. 2011 Mar; 72(3):388-96.
    View in: PubMed
    Score: 0.024
  11. Incremental cost-effectiveness of combined therapy vs medication only for youth with selective serotonin reuptake inhibitor-resistant depression: treatment of SSRI-resistant depression in adolescents trial findings. Arch Gen Psychiatry. 2011 Mar; 68(3):253-62.
    View in: PubMed
    Score: 0.024
  12. Treatment of Resistant Depression in Adolescents (TORDIA): week 24 outcomes. Am J Psychiatry. 2010 Jul; 167(7):782-91.
    View in: PubMed
    Score: 0.023
  13. Association of FKBP5 polymorphisms with suicidal events in the Treatment of Resistant Depression in Adolescents (TORDIA) study. Am J Psychiatry. 2010 Feb; 167(2):190-7.
    View in: PubMed
    Score: 0.022
  14. Substance use and the treatment of resistant depression in adolescents. J Am Acad Child Adolesc Psychiatry. 2009 Dec; 48(12):1182-92.
    View in: PubMed
    Score: 0.022
  15. Treatment of selective serotonin reuptake inhibitor-resistant depression in adolescents: predictors and moderators of treatment response. J Am Acad Child Adolesc Psychiatry. 2009 Mar; 48(3):330-9.
    View in: PubMed
    Score: 0.021
  16. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. Am J Psychiatry. 2009 Apr; 166(4):418-26.
    View in: PubMed
    Score: 0.021
  17. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA. 2008 Feb 27; 299(8):901-13.
    View in: PubMed
    Score: 0.020

© 2024 Kaiser Permanente